Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)
Anjali S. Advani(Cleveland Clinic), Wendy Stock(University of Chicago), Selina M. Luger(University of Pennsylvania), Eric Larsen(University of Massachusetts Chan Medical School), Steven Coutré(Georgetown University), Stephen P. Hunger(Children's Hospital of Philadelphia), Matthew C. Foster(University of North Carolina at Chapel Hill), Harry P. Erba(Michigan Center for Translational Pathology), Ben L. Sanford(Duke University), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Naomi Winick(The University of Texas Southwestern Medical Center), Richard M. Stone(Dana-Farber Cancer Institute), Peter M. Voorhees(Levine Cancer Institute), Richard A. Larson(Urbana University), William L. Carroll(NYU Langone Health), Kristin Coffan(Abramson Center for Jewish Life), Edy Parker(Unknown), Meenakshi Devidas(National Institutes of Health), Michaela Liedtke(Cancer Institute (WIA)), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Susan Geyer(University of South Florida), David F. Claxton(The University of Texas MD Anderson Cancer Center)
Cited by 47
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k